Edwards Lifesciences Corporation (EW) earnings on July 23, 2026

EW price around the earnings

82.63

Change: -1.4%

Start of the measured window End of the measured window

82.63 85.30 87.97 90.64 83.82

July 23, 2026 July 24, 2026

Price: green if it ends above the starting price; red if it ends below
Start of the measured window
End of the measured window
Market open
No trading (market closed)
Starting price

Price series around the event

Prior thesis

Prior outlook: Pessimistic Outcome: Accurate

Thesis published: 2026-07-23, 19:53 UTC
Results released: 2026-07-23, 20:15 UTC

Pre-release: Analysts are optimistic, but severe negative trend strength and trajectory collapse indicate a significant sell-off.

Context analyzed before publication

Trend: Trajectory collapsed from +7.5 to -89.8 over 6 days — extreme deterioration contexts priced-in expectations.

Analysts

Evidence

Analyst consensus: Buy
Consensus average (1-5): 1.71
Analysts covering the stock: 25
Average price target: 99
Lowest price target: 84
Highest price target: 110
Upside to price target: 18.9%
Quarterly earnings growth: 6.3%
Revenue growth: 16.7%
Forward EPS: 3.36
Trailing EPS: 1.85
Analyst moves in the last 60 days: 8

Strong buy: 4
Buy: 16
Hold: 8
Sell: 0
Strong sell: 0

Strong buy: 4
Buy: 16
Hold: 8
Sell: 0
Strong sell: 0

July 16, 2026 · Truist Securities: Maintains rating (Hold → Hold)
July 15, 2026 · Mizuho: Maintains rating (Outperform → Outperform)
July 13, 2026 · RBC Capital: Maintains rating (Outperform → Outperform)
July 8, 2026 · Citigroup: Maintains rating (Buy → Buy)
July 6, 2026 · Evercore ISI Group: Maintains rating (Outperform → Outperform)
June 30, 2026 · BTIG: Maintains rating (Buy → Buy)
June 16, 2026 · RBC Capital: Reiterates rating (Outperform → Outperform)
June 2, 2026 · TD Cowen: Maintains rating (Buy → Buy)

News and sentiment

Evidence

Sentiment

Sentiment: Constructive
Mention volume: Low
Normalized volume: 33%

News

Sources (8)

Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $95 (opens in a new tab) — Benzinga
Mizuho Maintains Outperform on Edwards Lifesciences, Raises Price Target to $105 (opens in a new tab) — Benzinga
RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $110 (opens in a new tab) — Benzinga
Merck To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday (opens in a new tab) — Benzinga
Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $110 (opens in a new tab) — Benzinga
Evercore ISI Group Maintains Outperform on Edwards Lifesciences, Raises Price Target to $100 (opens in a new tab) — Benzinga
Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday (opens in a new tab) — Benzinga
BTIG Maintains Buy on Edwards Lifesciences, Raises Price Target to $110 (opens in a new tab) — Benzinga

Technicals

Evidence

Average true range (ATR): 2.5%
Distance to 52-week high: -12.6%
14-day change (14d): -9.9%
30-day change (30d): -1.7%
30-day relative strength: -2.2%
SPY change (30d): +0.4%
Nearest support: 83.6
Nearest resistance: 84.41
Volume accumulation ratio (14d / 46d): 1.14

Trends

Evidence

Average earnings surprise: +5.3%

April 23, 2026: actual EPS 0.78 vs estimate 0.73 (surprise +7.3%)
February 10, 2026: actual EPS 0.58 vs estimate 0.62 (surprise -6.3%)
October 30, 2025: actual EPS 0.67 vs estimate 0.59 (surprise +12.6%)
July 24, 2025: actual EPS 0.67 vs estimate 0.62 (surprise +7.6%)

Expected move

Implied move: +2.2%
Source: Options chain

Reactions over its last 20 earnings

Median move: 5.5%
75th percentile move: 6.8%
90th percentile move: 10.6%
Up / down moves: 8 / 12
Average up move: +4.3%
Average down move: -7.7%

Monitoring and close

What Edwards Lifesciences Corporation reported

Status: Finished

Actual EPS	0.78
EPS estimate	0.74
EPS surprise	+5.4%
Revenue	$1,741 million
Revenue estimate	$1,700 million
Revenue surprise	+2.4%

Edwards Lifesciences reported Q2 earnings that beat estimates and raised its 2026 sales guidance, driving shares up 6%.

Sources (11)

Edwards Lifesciences Q2 Earnings Call Highlights (opens in a new tab) — MarketBeat
Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (opens in a new tab) — Zacks
Edwards Lifesciences Narrows Full-Year Sales Outlook After Second-Quarter Growth (opens in a new tab) — The Wall Street Journal
Edwards Stock Launches As Heart-Valve Replacements Beat On (opens in a new tab) — Investor's Business Daily
Edwards Lifesciences (NYSE:EW) Raises Guidance After Solid Q2 Earnings, Stock Surges 6% (opens in a new tab) — ChartMill
Heart-Valve Maker Edwards Lifesciences Launches On Beat-And-Raise Second Quarter (opens in a new tab) — Investor's Business Daily
Edwards Lifesciences Sees Q3 Adj EPS $0.71-$0.77 vs $0.74 Est; Sees Sales $1.630B-$1.710B vs $1.689B Est (opens in a new tab) — Benzinga
Edwards Lifesciences Affirms FY2026 Adj EPS Guidance of $2.95-$3.05 vs $3.01 Est; Raises FY2026 Sales Guidance from $6.500B-$6.900B to $6.600B-$6.900B vs $6.745B Est (opens in a new tab) — Benzinga
Edwards Lifesciences Q2 Adj. EPS $0.78 Beats $0.74 Estimate, Sales $1.741B Beat $1.700B Estimate (opens in a new tab) — Benzinga
Edwards Lifesciences Reports Second Quarter Results (opens in a new tab) — Yahoo
Edwards Lifesciences reported adjusted earnings of $0.78 per share, beating the $0.74 estimate, and sales of $1.741B, above the $1.700B forecast. — Benzinga

Pre-market second reading after the results

Verdict: Beat expectations

Heading into the open, the figures don't clearly confirm the prior scenario. In past cases, this setup has been optimistic 84.1% of the time (1115 occurrences).

How the stock reacted

Outcome: Accurate
Consolidated: -1.4%
Max favorable move (MFE): 3.4%
Max adverse move (MAE): 8.6%